D2C7-IT

N/A

Report date: 2024/10/11 20:00:59

Base Information

Drug NameD2C7-IT
Drug Alias NameD2C7-ITD2C7-(scdsFv)-PE38 KDELscds-D2C7 -PE38KDELD2C7-Immunotoxin
ClassificationBiologics > Protein drugs > Toxin
Mechanisms of ActionEpidermal growth factor receptor erbB1 modulatorsElongation factor 2 inhibitors
TargetsElongation factor 2Epidermal growth factor receptor erbB1
Therapy Area/IndicationsGlioblastomaGlioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesIstari Oncology IncDuke University
China Registration ClassN/A

Develop Information

Active CompaniesIstari Oncology IncDuke University
Inactive CompaniesN/A
Active IndicationsGlioblastomaGlioma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A